Delivery Technologies for Orally Inhaled Products: an Update

Chaeho Moon, Hugh D.C. Smyth, Alan Watts, Robert O. Williams

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Orally inhaled products have well-known benefits. They allow for effective local administration of many drugs for the treatment of pulmonary disease, and they allow for rapid absorption and avoidance of first-pass metabolism of several systemically acting drugs. Several challenges remain, however, such as dosing limitations, low and variable deposition of the drug in the lungs, and high drug deposition in the oropharynx region. These challenges have stimulated the development of new delivery technologies. Both formulation improvements and new device technologies have been developed through an improved understanding of the mechanisms of aerosolization and lung deposition. These new advancements in formulations have enabled improved aerosolization by controlling particle properties such as density, size, shape, and surface energy. New device technologies emerging in the marketplace focus on minimizing patient errors, expanding the range of inhaled drugs, improving delivery efficiency, increasing dose consistency and dosage levels, and simplifying device operation. Many of these new technologies have the potential to improve patient compliance. This article reviews how new delivery technologies in the form of new formulations and new devices enhance orally inhaled products.

Original languageEnglish (US)
Article number117
JournalAAPS PharmSciTech
Volume20
Issue number3
DOIs
StatePublished - Apr 1 2019

Fingerprint

drug
Technology
drugs
Equipment and Supplies
Pharmaceutical Preparations
lungs
patient compliance
Lung
Oropharynx
Patient Compliance
surface energy
dosage
respiratory tract diseases
Lung Diseases
drug therapy
compliance
metabolism
product
markets
energy

Keywords

  • delivery technology
  • dry powder inhaler
  • inhalation
  • orally inhaled product
  • smart inhaler

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Delivery Technologies for Orally Inhaled Products : an Update. / Moon, Chaeho; Smyth, Hugh D.C.; Watts, Alan; Williams, Robert O.

In: AAPS PharmSciTech, Vol. 20, No. 3, 117, 01.04.2019.

Research output: Contribution to journalReview article

Moon, Chaeho ; Smyth, Hugh D.C. ; Watts, Alan ; Williams, Robert O. / Delivery Technologies for Orally Inhaled Products : an Update. In: AAPS PharmSciTech. 2019 ; Vol. 20, No. 3.
@article{29dc3338a57849d88e50566eab9e6a16,
title = "Delivery Technologies for Orally Inhaled Products: an Update",
abstract = "Orally inhaled products have well-known benefits. They allow for effective local administration of many drugs for the treatment of pulmonary disease, and they allow for rapid absorption and avoidance of first-pass metabolism of several systemically acting drugs. Several challenges remain, however, such as dosing limitations, low and variable deposition of the drug in the lungs, and high drug deposition in the oropharynx region. These challenges have stimulated the development of new delivery technologies. Both formulation improvements and new device technologies have been developed through an improved understanding of the mechanisms of aerosolization and lung deposition. These new advancements in formulations have enabled improved aerosolization by controlling particle properties such as density, size, shape, and surface energy. New device technologies emerging in the marketplace focus on minimizing patient errors, expanding the range of inhaled drugs, improving delivery efficiency, increasing dose consistency and dosage levels, and simplifying device operation. Many of these new technologies have the potential to improve patient compliance. This article reviews how new delivery technologies in the form of new formulations and new devices enhance orally inhaled products.",
keywords = "delivery technology, dry powder inhaler, inhalation, orally inhaled product, smart inhaler",
author = "Chaeho Moon and Smyth, {Hugh D.C.} and Alan Watts and Williams, {Robert O.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1208/s12249-019-1314-2",
language = "English (US)",
volume = "20",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "American Association of Pharmaceutical Scientists",
number = "3",

}

TY - JOUR

T1 - Delivery Technologies for Orally Inhaled Products

T2 - an Update

AU - Moon, Chaeho

AU - Smyth, Hugh D.C.

AU - Watts, Alan

AU - Williams, Robert O.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Orally inhaled products have well-known benefits. They allow for effective local administration of many drugs for the treatment of pulmonary disease, and they allow for rapid absorption and avoidance of first-pass metabolism of several systemically acting drugs. Several challenges remain, however, such as dosing limitations, low and variable deposition of the drug in the lungs, and high drug deposition in the oropharynx region. These challenges have stimulated the development of new delivery technologies. Both formulation improvements and new device technologies have been developed through an improved understanding of the mechanisms of aerosolization and lung deposition. These new advancements in formulations have enabled improved aerosolization by controlling particle properties such as density, size, shape, and surface energy. New device technologies emerging in the marketplace focus on minimizing patient errors, expanding the range of inhaled drugs, improving delivery efficiency, increasing dose consistency and dosage levels, and simplifying device operation. Many of these new technologies have the potential to improve patient compliance. This article reviews how new delivery technologies in the form of new formulations and new devices enhance orally inhaled products.

AB - Orally inhaled products have well-known benefits. They allow for effective local administration of many drugs for the treatment of pulmonary disease, and they allow for rapid absorption and avoidance of first-pass metabolism of several systemically acting drugs. Several challenges remain, however, such as dosing limitations, low and variable deposition of the drug in the lungs, and high drug deposition in the oropharynx region. These challenges have stimulated the development of new delivery technologies. Both formulation improvements and new device technologies have been developed through an improved understanding of the mechanisms of aerosolization and lung deposition. These new advancements in formulations have enabled improved aerosolization by controlling particle properties such as density, size, shape, and surface energy. New device technologies emerging in the marketplace focus on minimizing patient errors, expanding the range of inhaled drugs, improving delivery efficiency, increasing dose consistency and dosage levels, and simplifying device operation. Many of these new technologies have the potential to improve patient compliance. This article reviews how new delivery technologies in the form of new formulations and new devices enhance orally inhaled products.

KW - delivery technology

KW - dry powder inhaler

KW - inhalation

KW - orally inhaled product

KW - smart inhaler

UR - http://www.scopus.com/inward/record.url?scp=85061815426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061815426&partnerID=8YFLogxK

U2 - 10.1208/s12249-019-1314-2

DO - 10.1208/s12249-019-1314-2

M3 - Review article

C2 - 30783904

AN - SCOPUS:85061815426

VL - 20

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 3

M1 - 117

ER -